PFG Investments LLC Decreases Stock Holdings in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX)

PFG Investments LLC cut its stake in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Free Report) by 85.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 51,750 shares of the biotechnology company's stock after selling 295,997 shares during the period. PFG Investments LLC owned about 0.09% of Aldeyra Therapeutics worth $298,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the stock. Geode Capital Management LLC lifted its stake in Aldeyra Therapeutics by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 1,119,555 shares of the biotechnology company's stock worth $5,588,000 after acquiring an additional 4,927 shares during the period. Wells Fargo & Company MN lifted its stake in Aldeyra Therapeutics by 1.9% in the fourth quarter. Wells Fargo & Company MN now owns 393,654 shares of the biotechnology company's stock worth $1,964,000 after acquiring an additional 7,348 shares during the period. Intech Investment Management LLC lifted its stake in Aldeyra Therapeutics by 62.7% in the fourth quarter. Intech Investment Management LLC now owns 23,806 shares of the biotechnology company's stock worth $119,000 after acquiring an additional 9,178 shares during the period. Barclays PLC lifted its position in shares of Aldeyra Therapeutics by 14.9% during the fourth quarter. Barclays PLC now owns 75,330 shares of the biotechnology company's stock valued at $376,000 after buying an additional 9,769 shares during the last quarter. Finally, Hsbc Holdings PLC purchased a new stake in shares of Aldeyra Therapeutics during the fourth quarter valued at about $52,000. 59.71% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms have commented on ALDX. Wall Street Zen raised shares of Aldeyra Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, June 21st. BTIG Research decreased their price target on shares of Aldeyra Therapeutics from $11.00 to $9.00 and set a "buy" rating for the company in a research report on Monday, April 7th. Finally, HC Wainwright reissued a "buy" rating and set a $10.00 price target on shares of Aldeyra Therapeutics in a research report on Monday, May 19th.

Insider Activity at Aldeyra Therapeutics

In related news, major shareholder Perceptive Advisors Llc sold 3,400,000 shares of the stock in a transaction that occurred on Thursday, April 3rd. The shares were sold at an average price of $1.42, for a total value of $4,828,000.00. Following the transaction, the insider now owns 5,875,851 shares in the company, valued at approximately $8,343,708.42. This represents a 36.65% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 8.50% of the stock is currently owned by insiders.

Aldeyra Therapeutics Stock Performance

Shares of Aldeyra Therapeutics stock traded down $0.08 during midday trading on Friday, hitting $3.79. The company had a trading volume of 2,539,401 shares, compared to its average volume of 841,350. The stock has a market cap of $227.02 million, a price-to-earnings ratio of -3.91 and a beta of 0.69. The company has a quick ratio of 6.49, a current ratio of 6.49 and a debt-to-equity ratio of 0.24. The company has a fifty day simple moving average of $2.59 and a 200 day simple moving average of $4.25. Aldeyra Therapeutics, Inc. has a 12-month low of $1.14 and a 12-month high of $7.20.

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.08. As a group, analysts predict that Aldeyra Therapeutics, Inc. will post -0.92 earnings per share for the current fiscal year.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.